-
-
-
-
-
-
-
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination
-
-
-
-
-
-
-
Xenetic extends Scripps Research collaboration for DNase platform
-
-
-
-
-
-
-
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma
-
-
-
-
-
-
-
Xenetic Biosciences (XBIO) Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and E
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Neutral Rating on Xenetic Biosciences (XBIO)
-
-
-
-
-
-
-
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
-
-
-
-
-
-
-
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
483,098 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


